TROPION-Breast02 -

Name: TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Uploaded: 2026-06-03T04:00:00+00:00
Duration: 5 min 13 s
Description: Datopotamab deruxtecan (Dato-DXd) is approved for the second-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC) and has also demonstrated si

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Project Oncology®
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Jorge Nieva, MD
- Jorge Nieva, MD
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Project Oncology®
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Urs Weber, MD
- Urs Weber, MD
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Project Oncology®
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Urs Weber, MD
- Urs Weber, MD
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Project Oncology®
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD; Nisha Joseph, MD
- Steve Jackson, PharmD
- Nisha Joseph, MD